Gentian Diagnostics' IVD segment focuses on developing and producing a range of diagnostic reagents and assays for medical laboratories and research institutions. This includes the Gentian Calprotectin Immunoassay, used for inflammation detection, and Cystatin C, a marker for renal function assessment. R&D efforts are directed towards enhancing assay sensitivity, specificity, and ease of use. The company leverages particle-enhanced turbidimetric immunoassays (PETIA) and other innovative technologies to improve diagnostic accuracy and efficiency. These products play a crucial role in early disease detection, treatment monitoring, and personalized medicine, ultimately improving patient outcomes and reducing healthcare costs. Future opportunities include expanding the IVD portfolio with novel biomarkers and exploring new applications in point-of-care testing and remote patient monitoring.

Gentian Diagnostics' veterinary diagnostics segment is dedicated to developing and commercializing diagnostic tests for animal health. A key product in this area is Canine CRP, an IVD test for the quantitative determination of Canine CRP in dog serum plasma, aiding in the diagnosis and monitoring of inflammation in dogs. The company's R&D efforts focus on expanding the range of veterinary diagnostic tests to cover a broader spectrum of animal diseases and conditions. This segment addresses the growing demand for advanced veterinary diagnostics, driven by increasing pet ownership and the rising importance of animal health management. Future opportunities include developing point-of-care veterinary diagnostic solutions and expanding into new animal species and disease areas.